What’s going on with the GSK share price?

Rupert Hargreaves explains why he thinks the outlook for the GSK share price could remain shrouded in uncertainty for the next year.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Businessman touching on number 2022 for preparation

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Over the past year, the GlaxoSmithKline (LSE: GSK) share price has underperformed the FTSE All-Share by 15%, excluding dividends. The index has returned 25%, excluding dividends, compared to GlaxoSmithKline’s return of just under 10%. 

Over the past five years, the performance of the stock is not much better. It has returned just 1.7%, compared to 13.8% for the FTSE All-Share.

Including dividends, the picture is only slightly better. Over the past year, the FTSE All-Share has produced a total return of 31% to Glaxo’s 22%. 

So what has been going on with the GSK share price, and can the company turn this performance around?

Rocky road ahead

Glaxo’s weak performance as an investment seems to stem from its equally weak fundamental performance as a business. City analysts believe the group is on track to report a net profit of £5.3bn this year, below the £5.7bn reported for 2020. Sales are also expected to be lower at £33.6bn, compared to £34.1bn in 2020. 

The pandemic had an impact on the group, but there also seem to be other factors at work here. The company’s treatment pipeline is widely believed to have less potential than that of its peers. It will also have to deal with the loss of exclusivity over its HIV medication Dolutegravir in 2028. 

On top of this, the company is planning to split itself in two next year. The plan to divide the Biopharma and Consumer Healthcare businesses that has been in the pipeline for some time.

What happens after the split is not yet clear. The company has told investors it will cut its dividend, and by divesting the Consumer Healthcare arm, the group will no longer have access to the stable profits from this division. That is where concerns about the potential of the Biotech side come in. 

Consumer Healthcare has been a cash cow for the group. Glaxo will need to invest heavily in its Biotech business to replace the lost income. It could be years before these investments yield any sort of return. 

GSK share price outlook 

So overall, Glaxo’s track record is mixed, the company is facing an uncertain future after its breakup, and the group’s coveted dividend is for the chop. Even though the stock yields 5.1% today, that is no use if the payout is only going to be cut next year. 

On the upside, CEO Emma Walmsley is optimistic that Glaxo can return to growth from 2022. She believes the company has an exciting period of growth between 2022 and 2026. And she may be right.

As the CEO, I am willing to give her the benefit of the doubt because she undoubtedly knows more about the inner workings of Glaxo than I do. 

However, this company has disappointed in the past, and it is not yet clear what shape the new businesses will take when it has completed the separation at the end of next year. 

With that being the case, I think investors are avoiding the GSK share price right now, due to uncertainty. And I agree. Based on the concerns outlined above, I would not buy the stock for my portfolio today.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

3 simple strategies that can help drive success in the stock market on a small budget

Christopher Ruane runs through a trio of strategic moves he reckons can help an investor as they aim to build…

Read more »

British union jack flag and Parliament house at city of Westminster in the background
Investing Articles

2 growth stocks backed by this British fund that’s soared 77.8% in just 3 years!

Our writer likes the look of this under-the-radar fund, especially with a pair of exciting growth stocks near the top…

Read more »

Shot of an young mixed-race woman using her cellphone while out cycling through the city
Investing Articles

Is there value in Baltic Classifieds — a soaring growth stock that brokers are buying?

Baltic Classifieds has surged after broker upgrades. Mark Hartley asks whether this FTSE 250 stock is really worth buying now.

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

£20k in an ISA? Here’s how it could be used to target £423 of passive income each month

Earning money from dividends in an ISA is one way to set up passive income streams. Our writer explains how…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

Which is better: £100,000 or a second income of £5,481 per year?

Dividend stocks and government bonds are both worthy ways of earning a second income. But which is a better choice…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

With interest rates falling, dividend stocks could be the key to passive income between now and 2030

In the years ahead, dividend stocks are likely to offer far more potential for passive income than savings accounts, says…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

After a 15% decline, should I move on from this FTSE 100 stock?

An investment in a FTSE 100 restructuring situation isn’t going the way our author had anticipated. Should he sit tight,…

Read more »

Pakistani multi generation family sitting around a table in a garden in Middlesbourgh, North East of England.
Investing Articles

If a 30-year-old puts £500 a month into a Stocks and Shares ISA, they could have £2.3m at retirement!

Starting early, picking wisely and investing £500 a month from age 30 might just lead to a multi-million-pound Stocks and…

Read more »